Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.45 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.45 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | BDKRB1 | P46663 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644122 | 0.93 | CACNA2D1 (0.46) | CACNA1BCACNA2D1CACNB1CACNA1CHCRTR1 | |
| SCHEMBL643321 | 0.92 | CACNA2D1 (0.40) | CACNA1BCACNA2D1CACNB1CACNA1CHCRTR1 | |
| SCHEMBL642812 | 0.83 | HCRTR1 (0.37) | HCRTR1HCRTR2BDKRB1SMN1; SMN2PSEN1 | |
| SCHEMBL3404248 | 0.82 | HCRTR1 (0.38) | HCRTR1HCRTR2BDKRB1MAPTTP53 | |
| SCHEMBL645171 | 0.81 | FKBP1A (0.37) | HCRTR1HCRTR2BDKRB1SMN1; SMN2LMNA | |
| SCHEMBL3412223 | 0.77 | BDKRB1 (0.36) | HCRTR1HCRTR2BDKRB1MAPTTP53 | |
| SCHEMBL4374697 | 0.76 | HCRTR1 (0.40) | HCRTR1HCRTR2BDKRB1MAPTPSEN1 | |
| SCHEMBL4299018 | 0.76 | HCRTR1 (0.36) | HCRTR1HCRTR2BDKRB1 | |
| SCHEMBL3407195 | 0.76 | HCRTR1 (0.39) | HCRTR1HCRTR2BDKRB1 | |
| SCHEMBL5121357 | 0.75 | HCRTR1 (0.39) | HCRTR1HCRTR2BDKRB1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150530-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-10-26 | — | — | EP | claimed |
| EP-2150530-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-02-10 | — | — | EP | claimed |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-18 | — | — | US | claimed |
| WO-2008131947-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | claimed |
| US-8119633-B2 | N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| EP-2150530-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-10-26 | — | — | EP | disclosed |
| EP-2150530-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| WO-2008131947-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312231-A1 | Substituted Sulfonamide Compounds | SULT2A1, SULT1A1, SCN1A | CACNA1B 279/4885CACNA2D1 1158/4885CACNB1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.